Literature DB >> 26232269

Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.

Masahiko Koda1, Shiho Tokunaga2, Toshiaki Okamoto2, Masanori Hodozuka2, Kennichi Miyoshi2, Manabu Kishina2, Yuki Fujise2, Jun Kato2, Tomomitsu Matono2, Takaaki Sugihara3, Kenji Oyama3, Keiko Hosho3, Jun-ichi Okano3, Yoshikazu Murawaki2, Suguru Kakite3, Eijiro Yamashita3.   

Abstract

BACKGROUND & AIMS: The aim of this study was to investigate the feasibility of ablative margin (AM) grading by magnetic resonance imaging (MRI) with Gd-EOB-DTPA administered prior to radiofrequency ablation (RFA), and to identify factors for achieving a sufficient AM and predictors for local tumor progression.
METHODS: A total of 124 hepatocellular carcinomas (HCCs) were treated by RFA after Gd-EOB-DTPA administration. MRI and enhanced CT were performed within seven hours and one month after RFA. The AM assessment was categorized using three grades: AM (+), low-intensity area with continuous high-intensity rim; AM zero, low-intensity area with discontinuous high-intensity rim; and AM (-), low-intensity area extends beyond the high-intensity rim. Patients were followed and local tumor progression was observed.
RESULTS: AM (+), AM zero, AM (-), and indeterminate were found in 34, 33, 26, and 31 nodules, respectively. The overall agreement rate between MRI and enhanced CT for the diagnosis of AM was 56.8%. The κ coefficient was 0.326 (p<0.001), indicating moderate agreement. Multivariate logistic regression analysis showed that a significant factor for the achievement of AM (+) on MRI was no contiguous vessels. The cumulative local tumor progression rates (0% at 1, 2, and 3 years) in 33 AM (+) nodules were significantly lower than those (3.6%, 11.5%, and 18.3% at 1, 2, and 3 years respectively) in 32 AM zero nodules. A multivariate Cox proportional hazards model identified tumor size as an independent predictor for local tumor progression.
CONCLUSION: Gd-EOB-DTPA-MRI enabled an early assessment of RFA effectiveness in the majority ofHCC nodules. Local tumor progression was not detected in AM (+) nodules during the follow-up.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ablative margin; Gadoxetic acid; Gd-EOB-DTPA; Hepatocellular carcinoma; Local tumor progression; Prognosis; Radiofrequency ablation

Mesh:

Substances:

Year:  2015        PMID: 26232269     DOI: 10.1016/j.jhep.2015.07.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Authors:  Kuniaki Fukuda; Kensaku Mori; Naoyuki Hasegawa; Katsuhiro Nasu; Kazunori Ishige; Yoshikazu Okamoto; Masanari Shiigai; Masato Abei; Manabu Minami; Ichinosuke Hyodo
Journal:  Jpn J Radiol       Date:  2019-05-17       Impact factor: 2.374

Review 2.  Local ablative treatments for hepatocellular carcinoma: An updated review.

Authors:  Antonio Facciorusso; Gaetano Serviddio; Nicola Muscatiello
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

3.  Safety margin assessment after microwave ablation of liver tumors: inter- and intrareader variability.

Authors:  Jan Schaible; Benedikt Pregler; Wolf Bäumler; Ingo Einspieler; Ernst-Michael Jung; Christian Stroszczynski; Lukas Philipp Beyer
Journal:  Radiol Oncol       Date:  2020-02-12       Impact factor: 2.991

4.  Safety and efficacy of pentazocine-midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma.

Authors:  Masanori Nakano; Yuichi Torisu; Chika Nakagawa; Kaoru Ueda; Tomoya Kanai; Chisato Saeki; Tsunekazu Oikawa; Masayuki Saruta
Journal:  JGH Open       Date:  2022-07-17

Review 5.  Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.

Authors:  Marco Gatti; Cesare Maino; Fatemeh Darvizeh; Alessandro Serafini; Eleonora Tricarico; Alessia Guarneri; Riccardo Inchingolo; Davide Ippolito; Umberto Ricardi; Paolo Fonio; Riccardo Faletti
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

Review 6.  Hepatocellular carcinoma: early-stage management challenges.

Authors:  Derek J Erstad; Kenneth K Tanabe
Journal:  J Hepatocell Carcinoma       Date:  2017-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.